TEVA-RANITIDINE 150 MG
RANITIDINE (RANITIDINE HYDROCHLORIDE) : 150 MG · DIN 00828564 · TEVA CANADA LIMITED
Health Canada status: CANCELLED POST MARKET
What is TEVA-RANITIDINE?
TEVA-RANITIDINE 150 MG contains RANITIDINE (RANITIDINE HYDROCHLORIDE) : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 00828564, held by TEVA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 22-Jun-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TEVA-RANITIDINE used for?
Duodenal/benign gastric ulcer, reflux esophagitis, post-op peptic ulcer, Zollinger-Ellison Syndrome, NSAID-induced lesions, prophylaxis of GI hemorrhage and Acid Aspiration Syndrome.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00828564 |
|---|---|
| Brand name | TEVA-RANITIDINE |
| Generic / active ingredient | RANITIDINE (RANITIDINE HYDROCHLORIDE) : 150 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 150 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A02BA02 RANITIDINE |
| AHFS class | 56:28.12 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 22-Jun-2018 |
| Original market date | 1989-12-31 00:00:00 |
How is it administered?
Oral: 150-300mg daily. IV/IM: 50mg every 6-8 hours. Renal adjustment: reduce dose by half if creatinine clearance < 50 mL/min. IV injection over at least 5 mins.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text.
How is it supplied?
Not explicitly detailed in provided text (mentions 150mg/300mg tablets, 15mg/mL solution, 25mg/mL injection).
Contraindications
Known hypersensitivity to ranitidine or to any ingredient in the formulation.
Warnings and precautions
Exclude gastric malignancy before therapy. May impair Vitamin B12 absorption. Avoid in patients with history of acute porphyria. Risk of community acquired pneumonia in certain populations.
What can be used instead?
Other Canadian products sharing ATC code A02BA02 RANITIDINE. 5 of 96 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| MAR-RANITIDINE | 150 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02443708 |
| MAR-RANITIDINE | 300 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02443716 |
| MAXIMUM STRENGTH ACID REDUCER WITHOUT PRESCRIPTION | 150 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02293471 |
| MINT-RANITIDINE | 150 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | DIN 02526379 |
| MINT-RANITIDINE | 300 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | DIN 02526387 |
| ACID REDUCER | 150 MG | TABLET | PENDOPHARM DIVISION OF PHARMASCIENCE INC | APPROVED | DIN 02291282 |
| ACID REDUCER | 150 MG | TABLET | PHARMASCIENCE INC | CANCELLED POST MARKET | DIN 02400103 |
| ACID REDUCER | 150 MG | TABLET | APOTEX INC | DORMANT | DIN 02296160 |
| ACID REDUCER | 75 MG | TABLET | MYLAN PHARMACEUTICALS ULC | CANCELLED POST MARKET | DIN 02237829 |
| ACID REDUCER | 75 MG | TABLET | APOTEX INC | DORMANT | DIN 02230507 |
Who else supplies RANITIDINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. RANITIDINE appears in 4061 registered pack listings across 3 markets, published on 3 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.